Amarin Corp Ads (AMRN)
$19.66 0.56 (2.77%)
19:56 EST AMRN Stock Quote Delayed 15 Minutes
Previous Close $19.66
Market Cap 5.77B
PE Ratio -
Volume (Avg. Vol.) 6.43M
Day's Range 18.68 - 19.89
52-Week Range 13.76 - 26.12
Dividend & Yield N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp Ads News
- From InvestorPlace
- From the Web
Amarin stock has some potential, but there are also many risks involved. Therefore, it doesn’t hurt to wait if you really want to buy these shares.
AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.
AstraZeneca out of the way. Plus, some key technical resistance is also dismantled, so it’s time to go long AMRN stock today.
During the past year, Amarin stock has been a laggard. But this could change in 2020 with the company's new drug poised for long-term growth.
Amarin stock has faded in recent weeks despite a spate of good news. That response suggests AMRN shares may have further to fall.
Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars
Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.
Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
Amarin stock is beating the indices and its sector etf's for a reason. Its chart suggests that there is an exciting move brewing.
Pharmaceutical companies are always difficult investment propositions, and Amarin shares proved why with its perhaps unjustifiably hyped drug Vascepa.
Amarin is doubling its sales force for Vascepa, a cholesterol-fighting drug, as potential competitors await results from their own trials.
By David Moadel
On the heels of a long-awaited FDA approval, Amarin stock is just what the doctor ordered. Here's what you can expect from AMRN in 2020.
Although the FDA approval is nice, fundamentally, Amarin stock is banking on a fish oil drug. Given its similarity to OTC counterparts, that doesn’t bode well for stakeholders.
The days of 50%-plus annual gains for Amarin stock are over, but that doesn't mean it's done moving higher. Here's why it should keep climbing in 2020.
Amarin is expecting an increase in sales for its fish-oil derived drug Vascepa. But investors are questioning if Amarin may be an M&A target.
From Market News Video
Investors in Amarin Corp plc (AMRN) saw new options become available today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for the new March 6th contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader